A Study of Teduglutide in Japanese People With Short Bowel Syndrome
Special Drug Use Investigation of Revestive Subcutaneous Injection 3.8 mg (All-case Surveillance)
Takeda
120 participants
Sep 1, 2021
OBSERVATIONAL
Conditions
Summary
The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with short bowel syndrome will receive an injection of teduglutide just under the skin (subcutaneous) according to their clinic's standard practice. The study doctors will check for side effects from teduglutide for 36 months.
Eligibility
Inclusion Criteria1
- All participants in Japan who received teduglutide will be enrolled in this post marketing surveillance.
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Teduglutide 0.05 mg/kg SC injection
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05023382